Lavipharm S.A Total Assets
Lavipharm S.A total assets. Based on the latest financial reports, Lavipharm S.A (LAVI) holds total assets worth €125.48 Million EUR (≈ $146.70 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Lavipharm S.A market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Lavipharm S.A (2014–2024)
Total assets of Lavipharm S.A from 2014 to 2024. This chart illustrates how Lavipharm S.A's total assets have evolved over time, based on quarterly financial data. See Lavipharm S.A (LAVI) share price today for real-time trading data and today's change.
Lavipharm S.A - Asset Composition Analysis
Lavipharm S.A Total Assets Breakdown (December 2024)
Lavipharm S.A total assets breakdown as of December 2024. Lavipharm S.A's total assets of €125.48 Million consist of 35.9% current assets and 64.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.5% |
| Accounts Receivable | €15.61 Million | 12.4% |
| Inventory | €19.46 Million | 15.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €49.68 Million | 39.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Lavipharm S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Lavipharm S.A to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lavipharm S.A's current assets represent 35.9% of total assets in 2024, an increase from 23.6% in 2014.
- Cash Position: Cash and equivalents constituted 4.5% of total assets in 2024, up from 2.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 11.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 39.6% of total assets.
Lavipharm S.A Competitors by Total Assets
Key competitors of Lavipharm S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medicon Hellas S.A.
AT:MEDIC
|
Greece | €31.81 Million |
|
Attica Holdings S.A.
AT:ATTICA
|
Greece | €1.30 Billion |
|
Mevaco S.A
AT:MEVA
|
Greece | €65.38 Million |
|
EL. D. Mouzakis S.A
AT:MOYZK
|
Greece | €61.03 Million |
|
Attica Publications S.A
AT:ATEK
|
Greece | €29.22 Million |
|
Flour Mills Kepenos S.A.
AT:KEPEN
|
Greece | €62.56 Million |
|
Kordellos Ch. Bros S.A
AT:KORDE
|
Greece | €61.90 Million |
|
National Bank of Greece S.A
AT:ETE
|
Greece | €83.36 Billion |
Lavipharm S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.15 | 1.28 | 1.21 |
| Quick Ratio | 0.65 | 0.86 | 0.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €5.88 Million | €9.85 Million | €3.73 Million |
Lavipharm S.A - Advanced Valuation Insights
This section examines the relationship between Lavipharm S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.09 |
| Latest Market Cap to Assets Ratio | 2.29 |
| Asset Growth Rate (YoY) | 9.3% |
| Total Assets | €125.48 Million |
| Market Capitalization | $287.04 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Lavipharm S.A's assets at a significant premium (2.29x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Lavipharm S.A's assets grew by 9.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Lavipharm S.A (2014–2024)
The table below shows the annual total assets of Lavipharm S.A from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €125.48 Million ≈ $146.70 Million |
+9.32% |
| 2023-12-31 | €114.79 Million ≈ $134.20 Million |
+0.54% |
| 2022-12-31 | €114.17 Million ≈ $133.47 Million |
+116.47% |
| 2021-12-31 | €52.74 Million ≈ $61.66 Million |
+4.15% |
| 2020-12-31 | €50.64 Million ≈ $59.20 Million |
+2.46% |
| 2019-12-31 | €49.42 Million ≈ $57.78 Million |
+17.96% |
| 2018-12-31 | €41.90 Million ≈ $48.98 Million |
-6.50% |
| 2017-12-31 | €44.81 Million ≈ $52.39 Million |
-6.99% |
| 2016-12-31 | €48.18 Million ≈ $56.32 Million |
-41.52% |
| 2015-12-31 | €82.38 Million ≈ $96.31 Million |
-1.72% |
| 2014-12-31 | €83.82 Million ≈ $98.00 Million |
-- |
About Lavipharm S.A
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; and over the counter (OTC) drugs,… Read more